No meaningful association between suicidal behavior and the use of IL-17A-neutralizing or IL-17RA-blocking agents

References

• Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41:401–407.
   PubMed Web of Science ®Google Scholar
• Jensen P, Ahlehoff O, Egeberg A, et al. Psoriasis and new-onset depression: a Danish nationwide cohort study. Acta Derm Venereol. 2016;96:39–42.
   PubMed Web of Science ®Google Scholar
• Kurd SK, Troxel AB, Crits-Christoph P, et al. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. Arch Dermatol. 2010;146:891–895.
   PubMed Web of Science ®Google Scholar
• Dalgard FJ, Gieler U, Tomas-Aragones L, et al. The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries. J Invest Dermatol. 2015;135:984–991.
   PubMed Web of Science ®Google Scholar
• Egeberg A, Hansen PR, Gislason GH, et al. Risk of self-harm and non-fatal suicide attempts, and completed suicide in patients with psoriasis - a population-based cohort study. Br J Dermatol. 2016 Apr 1. [Epub ahead of print]. DOI:10.1111/bjd.14633
   Web of Science ®Google Scholar
• Allison DJ, Ditor DS. The common inflammatory etiology of depression and cognitive impairment: a therapeutic target. J Neuroinflammation. 2014;11:151.
   PubMed Web of Science ®Google Scholar
• Dantzer R, O’Connor JC, Freund GG, et al. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 2008;9:46–56.
   PubMed Web of Science ®Google Scholar
• Han Q-Q, Yu J. Inflammation: a mechanism of depression? Neurosci Bull. 2014;30:515–523.
   PubMed Web of Science ®Google Scholar
• Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of major depression. Trend Immunol. 2006;27:24–31.
   PubMed Web of Science ®Google Scholar
• Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry. 2009;65:732.741.
   Web of Science ®Google Scholar
• Langley RG, Feldman SR, Han C, et al. Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to severe psoriasis: results from a randomized, double-blind, placebo-controlled phase III trial. J Am Acad Dermatol. 2010;63:457–465.
   PubMed Web of Science ®Google Scholar
• Tyring S, Gottlieb A, Papp K, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet. 2006;367:29–35.
   PubMed Web of Science ®Google Scholar
• Roblin X, Oltean P, Heluwaert F, et al. Panic attack with suicide: an exceptional ad- verse effect of infliximab. Dig Dis Sci. 2006;51:1056.
   PubMed Web of Science ®Google Scholar
• Farrell RJ, Shah SA, Lodhavia PJ, et al. Clinical experience with infliximab therapy in 100 patients with Crohn’s disease. Am J Gas Troenterol. 2000;95:3490–3497.
   PubMed Web of Science ®Google Scholar
• Papp KA, Reich K, Paul C, et al. A prospective phase 3, randomised, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2016 Feb 23. [Epub ahead of print]. DOI:10.1111/bjd.14493
   Web of Science ®Google Scholar
• Capuron L, Miller AH. Immune system to brain signaling: neuropsychopharmacological implications. Pharmacol Ther. 2011;130:226–238.
   PubMed Web of Science ®Google Scholar
• Beurel E, Harrington LE, Jope RS. Inflammatory Th17 cells promote depression-like behavior in mice. Biol Psychiatry. 2013;73:622–630.
   PubMed Web of Science ®Google Scholar
• Swardfager W, Herrmann N, Andreazza AC, et al. Poststroke neuropsychiatric symptoms: relationships with IL-17 and oxidative stress. Biomed Res Int. 2014;2014:245210.
   PubMed Web of Science ®Google Scholar
• Liu Q, Xin W, He P, et al. Interleukin-17 inhibits adult hippocampal neurogenesis. Sci Rep. 2014;19(4):7554.
   Web of Science ®Google Scholar
• Kleinschek MA, Owyang AM, Joyce-Shaikh B, et al. IL-25 regulates Th17 function in autoimmune inflammation. J Exp Med. 2007;204:161–70.E.
   PubMed Web of Science ®Google Scholar
• Bartlett HS, Million RP. Targeting the IL-17-T(H)17 pathway. Nat Rev Drug Discov. 2015;14:11–12.
   PubMed Web of Science ®Google Scholar
• Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm491872.htmX
   Google Scholar
• Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003729/smops/Positive/human_smop_000755.jsp&mid=WC0b01ac058001d127X
   Google Scholar
• Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm430969.htmX
   Google Scholar
• Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003943/smops/Positive/human_smop_000937.jsp&mid=WC0b01ac058001d127X
   Google Scholar
• Gaffen SL. An overview of IL-17 function and signaling. Cytokine. 2008;43:402–407.
   PubMed Web of Science ®Google Scholar
• Shen F, Gaffen SL. Structure-function relationships in the IL-17 receptor: implications for signal transduction and therapy. Cytokine. 2008;41:92–104.
   PubMed Web of Science ®Google Scholar
• Available from: https://www.drugs.com/nda/brodalumab_160719.html .
   Google Scholar
• Available from: http://www.medscape.com/viewarticle/866406?nlid=108537_1585&src=WNL_mdplsfeat_160726_mscpedit_derm&uac=208695CJ&spon=33&impID=1166274&faf=1
   Google Scholar
• Sanford M, McKeage K. Secukinumab: first global approval. Drugs. 2015;75:329–338.
   PubMed Web of Science ®Google Scholar
• Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis–results of two phase 3 trials. N Engl J Med. 2014;371:326–338.
   PubMed Web of Science ®Google Scholar
• Augustin M, Abeysinghe S, Mallya U, et al. Secukinumab treatment of plaque psoriasis shows early improvement in DLQI response - results of a phase II regimen-finding trial. J Eur Acad Dermatol Venereol. 2016;30:645–649.
   PubMed Web of Science ®Google Scholar
• van de Kerkhof PC, Griffiths CE, Reich K, et al. Secukinumab long-term safety experience: a pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol. 2016;75:83–98.
   PubMed Web of Science ®Google Scholar
• Markham A. Ixekizumab: first global approval. Drugs. 2016;76:901–905.
   PubMed Web of Science ®Google Scholar
• Zhu B, Edson-Heredia E, Guo J, et al. Itching is a significant problem and a mediator between disease severity and quality of life for patients with psoriasis: results from a randomized controlled trial. Br J Dermatol. 2014;171:1215–1219.
   PubMed Web of Science ®Google Scholar
• Strober B, Papp K, Leonardi C, et al. Integrated safety of ixekizumab in patients with moderate-to-severe Psoriasis: results from a pooled analysis of 7 clinical trials [abstract no. 3101]. 74th Annual Meeting; 2016 March 4–8; Washington (DC).
   Google Scholar
• Papp KA, Leonardi C, Menter A, et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med. 2012;366:1181–1189.
   PubMed Web of Science ®Google Scholar
• Papp K, Leonardi C, Menter A, et al. Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment. J Am Acad Dermatol. 2014;71:1183–1190.e3).
   PubMed Web of Science ®Google Scholar
• Gordon KB, Kimball AB, Chau D, et al. Impact of brodalumab treatment on psoriasis symptoms and health-related quality of life: use of a novel patient-reported outcome measure, the Psoriasis symptom inventory. Br J Dermatol. 2014;170:705–715.
   PubMed Web of Science ®Google Scholar
• Umezawa Y, Nakagawa H, Niiro H, et al. Long-term clinical safety and efficacy of brodalumab in the treatment of Japanese patients with moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2016 Jun 29. [Epub ahead of print]. DOI:10.1111/jdv.13785
   PubMed Web of Science ®Google Scholar
• Papp K, Reich K, Leonardi C, et al. Efficacy and safety of brodalumab in patients with moderate to severe plaque psoriasis: results of AMAGINE-1, a phase 3, randomized, double-blind, placebo-controlled study through week 12. [Poster 275]. 74th Annual Meeting; 2016 March 4–8; Washington (DC).
   Google Scholar
• Lebwohl M, Strober B, Menter A, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015;373:1318–1328.
   PubMed Web of Science ®Google Scholar
• Farahnik B, Beroukhim K, Abrouk M, et al. Brodalumab for the treatment of Psoriasis: a review of phase III trials. Dermatol Ther (Heidelb). 2016;6:111–124.
   PubMed Web of Science ®Google Scholar
• Strober B, Langley R, Blicharsk T. AMAGINE-3: a phase 3 study of efficacy and safety of brodalumab compared with Placebo and Ustekinumab in moderate to severe plaque psoriasis patients. [Poster 1146].74th Annual Meeting; 2016 March 4–8; Washington (DC).
   Google Scholar
• Thaçi D, Blauvelt A, Reich K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2015;73:400–409.
   PubMed Web of Science ®Google Scholar
• Griffiths CE, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386:541–551.
   PubMed Web of Science ®Google Scholar
• Chiricozzi A. Pathogenic role of IL-17 in psoriasis and psoriatic arthritis. Actas Dermosifiliogr. 2014;105(Suppl 1):9–20.
   PubMedGoogle Scholar
• Chiricozzi A, Krueger JG. IL-17 targeted therapies for psoriasis. Expert Opin Investig Drugs. 2013;22:993–1005.
   PubMed Web of Science ®Google Scholar
• Available from: http://www.ukmi.nhs.uk/applications/ndo/record_view_open.asp?newDrugID=5701
   Google Scholar
• Schmidt C. Suicidal thoughts end Amgen’s blockbuster aspirations for psoriasis drug. Nat Biotechnol. 2015;33:894–895.
   PubMed Web of Science ®Google Scholar
• Danesh MJ, Kimball AB. Brodalumab and suicidal ideation in the context of a recent economic crisis in the United States. J Am Acad Dermatol. 2016;74:190–192.
   PubMed Web of Science ®Google Scholar
• Celgene Corporation. Highlights of prescribing information. cited July 5 2015. Available from: http://www.otezla.com/otezla-prescribinginformation.pdf
   Google Scholar